Invivyd, Inc.

Listed Company

IVVDCIK 0001832038NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$53.43M

Net Income

$-52.50M

Total Assets

$276.88M

Equity

$241.54M

Shares Out

282.59M

Op. Cash Flow

$-58.13M

Business

Invivyd, Inc. is a biopharmaceutical company that develops monoclonal antibody therapies to protect populations from viral infectious diseases, beginning with SARS‑CoV‑2. It offers PEMGARDA (pemivibart), authorized for emergency use as pre‑exposure prophylaxis for certain immunocompromised patients, and is advancing next‑generation mAbs including VYD2311 and additional discovery‑stage candidates. Its operations encompass discovery and engineering, industrial virology and variant surveillance, clinical development and manufacturing partnerships (including with WuXi Biologics) and commercialization activities. It currently commercializes in the U.S. via specialty distributors, infusion centers and clinics while exploring regulatory and partnership opportunities internationally.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	53	25	0	—	—
Cost of product revenue	4	2	0	—	—
Research and development expense	38	137	159	179	183
Selling, general and administrative	67	63	49	47	37
Total operating costs and expenses	109	202	213	248	227
Loss from operations	−56	−177	−213	−248	−227
Other income, net	3	7	14	7	118,000
Total other income, net	3	7	14	7	118,000
Net loss	−53	−170	−199	−241	−227
Unrealized (loss) gain, net of tax	−36,000	8,000	259,000	−264,000	−8,000
Comprehensive loss	−53	−170	−198	−242	−227
Net loss per share attributable to common stockholders, basic	−0.3	−1.43	−1.81	−2.23	−5.32
Net loss per share attributable to common stockholders, diluted	−0.3	−1.43	−1.81	−2.23	−5.32
Weighted-average common shares outstanding, diluted	172	119	110	108	43
Weighted-average common shares outstanding, basic	172	119	110	108	43

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	227	69	201	92	542
Accounts receivable, net	14	11	0	—	—
Prepaid expenses and other current assets	7	20	24	5	25
Total current assets	247	101	225	377	617
Inventory	25	26	0	—	—
Property and equipment, net	1	2	2	2	83,000
Operating lease right-of-use assets	2	1	2	4	2
Other non-current assets	110,000	34,000	175,000	191,000	3
Total assets	277	130	229	383	620
Accounts payable	14	10	8	2	6
Accrued expenses	19	50	41	22	56
Operating lease liabilities	1	1	1	2	308,000
Other current liability	52,000	27,000	35,000	44,000	—
Total current liabilities	34	62	50	25	62
Operating lease liabilities, non-current	1	0	722,000	2	1
Total liabilities	35	62	52	27	62
Commitments and contingencies (Note 9)	—	—	—	—	—
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 281,987,033 shares issued and outstanding at December 31, 2025; 119,835,162 shares issued and outstanding at December 31, 2024	28,000	12,000	11,000	11,000	11,000
Additional paid-in capital	1,196	970	910	890	850
Accumulated other comprehensive loss	−41,000	−5,000	−13,000	−272,000	−8,000
Accumulated deficit	−955	−902	−732	−533	−292
Total stockholders' equity	242	68	177	356	558
Total liabilities and stockholders' equity	277	130	229	383	620

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−52	−170	−199	−241	−227
Stock-based compensation expense	12	20	19	22	18
Amortization of operating lease right-of-use assets	1	2	2	421,000	0
Depreciation and amortization expense	755,000	1	480,000	—	—
Other non-cash adjustments	298,000	0	—	—	—
Accounts receivable	−3	−11	0	—	—
Inventory	−373,000	−25	0	—	—
Prepaid expenses and other current assets	13	3	−19	20	−23
Other non-current assets	−77,000	141,000	16,000	3	−3
Accounts payable	3	2	6	−4	−2
Accrued expenses	−31	9	19	−35	51
Operating lease liabilities	−1	−2	−2	−475,000	0
Other current liabilities	23,000	−8,000	−10,000	44,000	0
Other non-current liabilities	0	−700,000	700,000	−5,000	1,000
Net cash used in operating activities	−58	−170	−173	−220	−185
Purchases of property and equipment	−155,000	−140,000	−615,000	−2	−84,000
Net cash used in investing activities	−155,000	−140,000	281	−231	−51
Proceeds from exercises of stock options	411,000	420,000	955,000	241,000	—
Proceeds from issuance of common stock under the employee stock purchase plan	254,000	223,000	240,000	269,000	—
Proceeds from at-the-market offering, net of commissions	33	39	—	—	—
Proceeds from underwritten public offering, net of underwriting discounts and commissions	183	0	—	—	—
Payments for at-the-market offering costs	−336,000	−597,000	—	—	—
Payments for underwritten public offering costs	−633,000	0	—	—	—
Net cash provided by financing activities	216	39	1	506,000	663
Effect of exchange rate changes on cash and cash equivalents	0	8,000	0	—	—
Net increase (decrease) in cash and cash equivalents	157	−131	109	−450	427
Deferred offering costs in accrued expenses	171,000	0	273,000	0	—
Deferred offering costs in accounts payable	88,000	71,000	0	—	—
Property and equipment included in accrued expenses	206,000	0	—	—	—
Property and equipment included in accounts payable	33,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro